glucagon has been researched along with nevirapine in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (nevirapine) | Trials (nevirapine) | Recent Studies (post-2010) (nevirapine) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 3,212 | 509 | 1,108 |
| Protein | Taxonomy | glucagon (IC50) | nevirapine (IC50) |
|---|---|---|---|
| Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
| Chain A, Reverse transcriptase/ribonuclease H | Human immunodeficiency virus 1 | 1.165 | |
| Prothrombin | Bos taurus (cattle) | 1.15 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | 1.4504 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 2.05 | |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 1.4353 | |
| Imidazoleglycerol-phosphate dehydratase | Saccharomyces cerevisiae S288C | 1.7 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.181 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.181 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.69 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.7 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 5.75 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.18 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.071 | |
| Protease | Human immunodeficiency virus 1 | 0.101 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 3.995 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bordenave, B; Claxton, S; Henry, K; Kane, E; Klebert, M; Powderly, WG; Tebas, P; Yarasheski, K | 1 |
1 trial(s) available for glucagon and nevirapine
| Article | Year |
|---|---|
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cyclopropanes; Drug Therapy, Combination; Female; Glucagon; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Insulin Resistance; Lipids; Lipoproteins; Male; Nevirapine; Oxazines; Pilot Projects; RNA, Viral; Viral Load | 2004 |